SYK and Alzheimer disease: Thus, Nilvadipine has the potential to be a multimodal AD treatment through the novel target of Syk; and a Phase III clinical trial of Nilvadipine in AD has recently been successfully completed in Europe (ClinicalTrials.gov: NCT02017340; Lawlor et al., 2014).